| Autor: |
Robat-Jazi B; Department of Medical Immunology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran. behruz.robatjazi@yahoo.com., Ghorban K; Department of Medical Immunology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran AND Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran. kh.ghorban@gmail.com., Gholami M; Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran AND Department of Microbiology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran. Mohammadg19@gmail.com., Samizadeh E; Department of Pathology, Imam Reza Hospital, Aja University of Medical Sciences, Tehran, Iran. esmaeil.samizadeh@gmail.com., Aghazadeh Z; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. z.aghazadeh76@gmail.com., Shahrbaf MA; Department of Medicine, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. aminshahrbaf41@gmail.com., Dadmanesh M; Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran AND Department of Infectious Diseases, School of Medicine, Aja University of Medical Sciences, Tehran, Iran. dr.dadmanesh@gmail.com., Hosseini Rouzbahani N; Department of Medical Immunology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran AND Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran. signet.h313@gmail.com., Mirshafiey A; Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. mirshafiey@tums.ac.ir. |
| Abstrakt: |
coronavirus disease of 2019 (COVID-19) can be complicated by acute respiratory distress syndrome (ARDS) and may be associated with cytokine storm and multiorgan failure. Anti-inflammatory agents, such as systemic corticosteroids, monoclonal antibodies, and nonsteroidal anti-inflammatory drugs (NSAIDs) can be used for this purpose. In this study, we evaluated the immunomodulatory effect of mannuronic acid (M2000), which is a novel NSAID, on COVID-19-related cytokine storms. This study was conducted in vitro on blood samples of 30 COVID-19 patients who presented with ARDS to a referral center. Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples and incubated with phorbol myristate acetate for 24 hours. M2000 was administered with the dosages of 25 µg/well and 50 µg/well after 4 hours of incubation at 37°C. The quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to assess mRNA gene expression. Enzyme-linked immunosorbent assay (ELISA) was performed to evaluate the supernatant PBMC levels of interleukin (IL)-6, IL-17, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ. Both mRNA expression and the supernatant PBMC levels of IL-17, TNF-α, IL‑6, and IFN‑γ were decreased in PBMCs of COVID-19 patients treated with M2000 compared with the control group. For the first time, it was observed that M2000 could be effective in alleviating the inflammatory cascade of COVID-19 patients based on an in vitro model. After further studies in vitro and in animal models, M2000 could be considered a novel NSAID drug in COVID-19 patients. |
